发明名称 Assay for measuring cell-mediated immunoresponsiveness
摘要 The present invention relates generally to the field of immunological-based diagnostic assays. More particularly, the present invention contemplates a method for measuring cell-mediated immunoresponsiveness. The present invention further enables determination of the immunosuppressive effects of disease conditions, therapeutic agents and environmental contaminants. The assay of the present invention is also capable of integration into pathology architecture to provide a diagnostic reporting system and to facilitate point of care clinical management.
申请公布号 US9459253(B2) 申请公布日期 2016.10.04
申请号 US201013516150 申请日期 2010.12.21
申请人 Cellestis Limited 发明人 Boyle Jeff;De Las Heras Rachel
分类号 A61K38/00;C12N5/00;C12N5/02;G01N33/569;G01N33/50 主分类号 A61K38/00
代理机构 Seed IP Law Group PLLC 代理人 Seed IP Law Group PLLC
主权项 1. An in vitro method for determining immunoresponsiveness or immunosuppression in lymphocytes that are present in a sample source of lymphocytes obtained from a test subject, comprising: (i) contacting in vitro in a blood collection tube a sample source of lymphocytes obtained from the test subject with at least two agents which potentiate adaptive and innate immune systems to exert a synergistic response in vitro, wherein the lymphocytes comprise T-lymphocytes and NK-lymphocytes and wherein the at least two agents comprise at least one adaptive immune stimulant that stimulates the T-lymphocytes and is selected from a T-cell receptor agonist and a T-cell receptor-independent T-cell stimulant, and at least one TLR agonist that stimulates the NK-lymphyocytes; (ii) measuring a first level of at least one immune effector molecule produced by immune cells that are present in the sample source of lymphocytes following said step of contacting, said immune effector molecule being selected from complement component C5a, Groα (CXCL1), sICAM-1 (CD54), IFN-γ (Type II IFN), IL-1α (IL-1F1), IL-1β (IL-1F2), IL-1ra (IL-1F3), IL-6, IL-8 (CXCL8), IL-10, IL-16 (LCF), IL-17, IP-10 (CXCL10), I-TAC (CXCL11), MCP-1 (CCL2), MIF (GIF), MIP-1α (CCL3), MIP-1β (CCL4), Serpin E1 (PAI-1), RANTES (CCL5), TNF-α (TNFSF2), and MIG (CXCL9); and (iii) comparing the first level measured in (ii) to a control level of said at least one immune effector molecule that is produced by control immune cells following contact with the at least two agents which potentiate adaptive and innate immune systems, said control immune cells being present in a control sample source that contains control lymphocytes and that has been obtained from a control subject known to have normal cell-mediated immune response activity, and therefrom determining immunoresponsiveness or immunosuppression in the lymphocytes that are present in the sample source of lymphocytes.
地址 Chadstone AU